BioMarin Pharmaceutical Inc. (BM8.DE)
EUR 61.96
(-1.71%)
EUR 61.96
(-1.71%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.09 Billion USD | 1.18% |
| 2022 | 1.08 Billion USD | 0.37% |
| 2021 | 1.07 Billion USD | 0.37% |
| 2020 | 1.07 Billion USD | 26.77% |
| 2019 | 848.12 Million USD | 2.13% |
| 2018 | 830.41 Million USD | -29.29% |
| 2017 | 1.17 Billion USD | 71.9% |
| 2016 | 683.23 Million USD | 3.16% |
| 2015 | 662.28 Million USD | 0.66% |
| 2014 | 657.97 Million USD | 0.37% |
| 2013 | 655.56 Million USD | 88.26% |
| 2012 | 348.22 Million USD | -0.03% |
| 2011 | 348.32 Million USD | -7.73% |
| 2010 | 377.52 Million USD | -24.05% |
| 2009 | 497.08 Million USD | 602.68% |
| 2008 | 70.74 Million USD | -85.96% |
| 2007 | 503.68 Million USD | 118.3% |
| 2006 | 230.72 Million USD | 2.88% |
| 2005 | 224.25 Million USD | -17.2% |
| 2004 | 270.84 Million USD | 116.67% |
| 2003 | 125 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 5.55 Million USD | 6589.16% |
| 2000 | 83 Thousand USD | -25.23% |
| 1999 | 111 Thousand USD | 11.0% |
| 1998 | 100 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.09 Billion USD | 0.07% |
| 2023 Q3 | 1.09 Billion USD | 0.95% |
| 2023 Q2 | 1.08 Billion USD | 0.09% |
| 2023 Q4 | 1.09 Billion USD | 0.04% |
| 2023 FY | 1.09 Billion USD | 1.18% |
| 2023 Q1 | 1.08 Billion USD | 0.09% |
| 2022 Q4 | 1.08 Billion USD | 0.09% |
| 2022 FY | 1.08 Billion USD | 0.37% |
| 2022 Q1 | 1.08 Billion USD | 0.09% |
| 2022 Q2 | 1.08 Billion USD | 0.09% |
| 2022 Q3 | 1.08 Billion USD | 0.09% |
| 2021 Q2 | 1.07 Billion USD | 0.09% |
| 2021 FY | 1.07 Billion USD | 0.37% |
| 2021 Q3 | 1.07 Billion USD | 0.09% |
| 2021 Q4 | 1.07 Billion USD | 0.09% |
| 2021 Q1 | 1.07 Billion USD | 0.09% |
| 2020 Q1 | 852.67 Million USD | 0.54% |
| 2020 Q3 | 1.44 Billion USD | 0.36% |
| 2020 Q4 | 1.07 Billion USD | -25.77% |
| 2020 FY | 1.07 Billion USD | 26.77% |
| 2020 Q2 | 1.44 Billion USD | 69.27% |
| 2019 Q2 | 839.16 Million USD | 0.53% |
| 2019 Q3 | 843.61 Million USD | 0.53% |
| 2019 Q4 | 848.12 Million USD | 0.53% |
| 2019 FY | 848.12 Million USD | 2.13% |
| 2019 Q1 | 834.76 Million USD | 0.52% |
| 2018 Q4 | 830.41 Million USD | -30.82% |
| 2018 FY | 830.41 Million USD | -29.29% |
| 2018 Q1 | 1.18 Billion USD | 0.73% |
| 2018 Q2 | 1.19 Billion USD | 0.73% |
| 2018 Q3 | 1.2 Billion USD | 0.73% |
| 2017 Q3 | 1.16 Billion USD | 72.44% |
| 2017 Q4 | 1.17 Billion USD | 0.72% |
| 2017 Q2 | 676.2 Million USD | -2.13% |
| 2017 Q1 | 690.93 Million USD | 1.13% |
| 2017 FY | 1.17 Billion USD | 71.9% |
| 2016 FY | 683.23 Million USD | 3.16% |
| 2016 Q2 | 670.1 Million USD | 0.31% |
| 2016 Q1 | 668 Million USD | 0.86% |
| 2016 Q3 | 675.63 Million USD | 0.83% |
| 2016 Q4 | 683.23 Million USD | 1.13% |
| 2015 Q1 | 655.49 Million USD | -0.38% |
| 2015 Q3 | 667.79 Million USD | 0.95% |
| 2015 Q4 | 662.28 Million USD | -0.82% |
| 2015 FY | 662.28 Million USD | 0.66% |
| 2015 Q2 | 661.49 Million USD | 0.92% |
| 2014 Q4 | 657.97 Million USD | 0.17% |
| 2014 Q2 | 650.87 Million USD | -1.59% |
| 2014 Q3 | 656.88 Million USD | 0.92% |
| 2014 Q1 | 661.41 Million USD | 0.89% |
| 2014 FY | 657.97 Million USD | 0.37% |
| 2013 Q4 | 655.56 Million USD | 737.14% |
| 2013 FY | 655.56 Million USD | 88.26% |
| 2013 Q2 | 109.82 Million USD | -0.02% |
| 2013 Q3 | 78.31 Million USD | -28.69% |
| 2013 Q1 | 109.84 Million USD | -68.45% |
| 2012 Q1 | 348.32 Million USD | -0.0% |
| 2012 Q4 | 348.22 Million USD | -0.02% |
| 2012 FY | 348.22 Million USD | -0.03% |
| 2012 Q3 | 348.3 Million USD | -0.0% |
| 2012 Q2 | 348.3 Million USD | -0.01% |
| 2011 Q1 | 377.52 Million USD | 0.0% |
| 2011 Q3 | 348.33 Million USD | -7.73% |
| 2011 Q4 | 348.32 Million USD | -0.0% |
| 2011 Q2 | 377.52 Million USD | -0.0% |
| 2011 FY | 348.32 Million USD | -7.73% |
| 2010 Q1 | 497.08 Million USD | 0.0% |
| 2010 FY | 377.52 Million USD | -24.05% |
| 2010 Q4 | 377.52 Million USD | -24.05% |
| 2010 Q3 | 497.08 Million USD | 0.0% |
| 2010 Q2 | 497.08 Million USD | 0.0% |
| 2009 Q2 | 497.08 Million USD | -12.39% |
| 2009 Q3 | 497.08 Million USD | 0.0% |
| 2009 Q4 | 497.08 Million USD | 0.0% |
| 2009 FY | 497.08 Million USD | 602.68% |
| 2009 Q1 | 567.4 Million USD | -0.07% |
| 2008 Q3 | 497.24 Million USD | -1.16% |
| 2008 Q1 | 503.36 Million USD | -0.06% |
| 2008 FY | 70.74 Million USD | -85.96% |
| 2008 Q2 | 503.06 Million USD | -0.06% |
| 2008 Q4 | 567.82 Million USD | 14.2% |
| 2007 Q4 | 503.68 Million USD | -11.77% |
| 2007 Q2 | 571.49 Million USD | 131.16% |
| 2007 FY | 503.68 Million USD | 118.3% |
| 2007 Q1 | 247.23 Million USD | 7.15% |
| 2007 Q3 | 570.87 Million USD | -0.11% |
| 2006 Q2 | 374.01 Million USD | -5.28% |
| 2006 FY | 230.72 Million USD | 2.88% |
| 2006 Q4 | 230.72 Million USD | -23.06% |
| 2006 Q3 | 299.87 Million USD | -19.82% |
| 2006 Q1 | 394.88 Million USD | 76.08% |
| 2005 Q2 | 228.11 Million USD | 34.45% |
| 2005 Q1 | 169.65 Million USD | -37.36% |
| 2005 FY | 224.25 Million USD | -17.2% |
| 2005 Q4 | 224.25 Million USD | -0.83% |
| 2005 Q3 | 226.14 Million USD | -0.86% |
| 2004 Q3 | 270.8 Million USD | 44.81% |
| 2004 Q2 | 187 Million USD | 49.6% |
| 2004 Q1 | 125 Million USD | 0.0% |
| 2004 FY | 270.84 Million USD | 116.67% |
| 2004 Q4 | 270.84 Million USD | 0.01% |
| 2003 Q3 | 125 Million USD | 0.0% |
| 2003 Q4 | 125 Million USD | 0.0% |
| 2003 Q2 | 125 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | 125 Million USD | 0.0% |
| 2002 Q4 | - USD | -100.0% |
| 2002 Q3 | 2.91 Million USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q1 | 5.22 Million USD | -5.96% |
| 2002 FY | - USD | -100.0% |
| 2001 Q4 | 5.55 Million USD | 2203.73% |
| 2001 Q2 | 296 Thousand USD | 289.47% |
| 2001 FY | 5.55 Million USD | 6589.16% |
| 2001 Q1 | 76 Thousand USD | -8.43% |
| 2001 Q3 | 241 Thousand USD | -18.58% |
| 2000 FY | 83 Thousand USD | -25.23% |
| 2000 Q4 | 83 Thousand USD | -8.79% |
| 2000 Q3 | 91 Thousand USD | -6.19% |
| 2000 Q2 | 97 Thousand USD | -5.83% |
| 2000 Q1 | 103 Thousand USD | -7.21% |
| 1999 Q4 | 111 Thousand USD | 11.0% |
| 1999 FY | 111 Thousand USD | 11.0% |
| 1999 Q2 | 26.1 Million USD | 26000.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | -99.62% |
| 1998 FY | 100 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BioNTech SE | 219.1 Million EUR | -400.115% |
| CureVac N.V. | 41.85 Million EUR | -2517.751% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | -58.851% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | -58.851% |
| BRAIN Biotech AG | 4.65 Million EUR | -23419.017% |
| Formycon AG | 29.48 Million EUR | -3616.174% |
| Heidelberg Pharma AG | 5.83 Million EUR | -18690.601% |
| Medigene AG | 2.95 Million EUR | -37044.102% |